Scalable production frameworks are central to the advancement of cell and gene therapies from early scientific study to global research and market settings. As the field matures, there is a need for standardized, modular manufacturing, the automation of manufacturing, closed-system processing, digital integration, and best practices that facilitate consistent, high-quality outcomes across various modalities and therapeutic areas. Ensuring that the next generation of transformative therapies moves from manufacturer to patient safety, efficacy, and consistency in product quality, reproducibility, and regulatory compliance.